2023
DOI: 10.3389/fpubh.2023.1159348
|View full text |Cite
|
Sign up to set email alerts
|

The role of kurtosis and kurtosis-adjusted energy metric in occupational noise-induced hearing loss among metal manufacturing workers

Abstract: BackgroundNoise energy has been well-established to increase the risk of occupational noise-induced hearing loss (NIHL). However, the role of noise temporal structure (expressed by kurtosis) or its combination with energy metrics (e.g., kurtosis-adjusted cumulative noise exposure, adj-CNE) in occupational NIHL was still unclear.MethodsA cross-sectional survey of 867 Chinese workers, including 678 metal manufacturing workers and 189 workers exposed to Gaussian noise, was conducted. Noise energy metrics, includi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 39 publications
(91 reference statements)
0
1
0
Order By: Relevance
“…According to a systematic review, the noise-induced permanent threshold shift after 10 years of exposure at L ex,8h = 100 dB of 3-6 kHz is 27 dB [3]. A recent study on manufacturing workers has shown that the mean prevalence of high-frequency NIHL is 41.64% [4]. Although current research on NIHL drug therapy includes anti-inflammatory (such as dexamethasone [5], methylprednisolone [6], and curcumin [7]), antioxidant (such as resveratrol [8] and salicylate Trolox [9]), and antiapoptotic drugs (such as all-trans retinoic acid [10] and AM-111 [11]), there are no specific drugs for NIHL [1].…”
Section: Introductionmentioning
confidence: 99%
“…According to a systematic review, the noise-induced permanent threshold shift after 10 years of exposure at L ex,8h = 100 dB of 3-6 kHz is 27 dB [3]. A recent study on manufacturing workers has shown that the mean prevalence of high-frequency NIHL is 41.64% [4]. Although current research on NIHL drug therapy includes anti-inflammatory (such as dexamethasone [5], methylprednisolone [6], and curcumin [7]), antioxidant (such as resveratrol [8] and salicylate Trolox [9]), and antiapoptotic drugs (such as all-trans retinoic acid [10] and AM-111 [11]), there are no specific drugs for NIHL [1].…”
Section: Introductionmentioning
confidence: 99%